Lonza has announced the installation of a new Harro Hӧfliger Modu-C MS encapsulation unit at its product development and manufacturing facility in Tampa, FL. The company said that installation and validation of the unit are expected to be complete by the end of the month. Lonza also said that it expects to open a new dispensing area and processing suites for highly potent actives at the facility by May 2018.
Capsugel, which was acquired by Lonza in 2017, has a Center of Excellence specializing in micro-dosing in Tampa. Capsugel acquired the Tampa Xcelience micro-dosing facility in 2015.
In early 2017, Capsugel announced the addition of a Harro Hӧfliger Modu-C MS systems at its Bend, Oregon facility, which was formerly known as Bend Research before its acquisition by Capsugel in 2013. Both the Tampa and Bend facilities also have Xcelodose micro-dosing systems.
Lonza Pharma & Biotech Head of Chemical Division Gordon Bates said, “We listen to our customers’ needs and invest accordingly. Expanding our capability into commercial-scale encapsulation responds to our customers’ desire to maintain programs at the site from clinical development to commercialization.”
Tampa Site Head Robert Beland commented, “Our integrated full-service offering can reduce drug development timelines, complexity and costs, which are priorities for our customers. The Tampa site is well known for exceptional capabilities in Xcelodose-based encapsulation, inclusive of highly potent compound applications. The addition of the new Harro unit allows us to offer our customers the option of one partner from concept to market for their encapsulated drug products.”
Read the Lonza press release.
